385 Oyster Point #9A
South San Francisco
73 articles with Vaxart, Inc.
Vaxart, Inc. announced the publication of the comprehensive results from a preclinical trial of its chikungunya vaccine in the peer reviewed journal, Vaccine.
Vaxart Doses First Patient in Randomized Cohort of Bivalent Norovirus Vaccine Phase 1b Clinical Trial
Vaxart, Inc. announced it has started dosing subjects in the randomized cohort of the Phase 1b bivalent norovirus vaccine clinical trial.
100% Survival Against Lethal H5N1 Avian Flu Challenge in Ferret Study
Vaxart, Inc. announced the pricing of an underwritten public offering of 9,090,010 shares of common stock, and common warrants to purchase up to an aggregate of 9,090,010 shares of common stock.
Vaxart, Inc. announced participation in two upcoming global medical meetings in April.
Vaxart, Inc. announced the completion of dosing of the lead-in cohort in the Phase 1b bivalent norovirus vaccine clinical trial with its oral norovirus GII.4 vaccine.
When it comes to biotech and pharma innovation few places stand out like the Biotech Bay. The area is home to a plethora of innovative companies that are shaping the future of medical treatment for a variety of diseases and conditions on a daily basis.
Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the closing of its previously announced registered direct offering of 1,200,000 shares of its common stock at a price of $2.50 per share
First Dosing with Norovirus GII.4 Oral Tablet Vaccine Scheduled for Week of March 18
Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biopharmaceutical company focused on the development of oral recombinant vaccines based on its proprietary oral vaccine platform, today announced that it has entered into definitive agreements with certain institutional investors for the purchase and sale in a registered direct offering priced at-the-market of 1,200,000 shares of the Vaxart’s common stock,
Initiation of Two Norovirus Vaccine Trials Expected in 1H 2019
Vaxart, Inc. today announced that Sean Tucker, Ph.D., chief scientific officer, will present summary data from the Phase 2 Challenge Study of its H1 influenza oral tablet vaccine at the World Vaccine and Immunotherapy Congress West Coast 2018, taking place from November 28-30, 2018 in San Diego, California.
10/15/2018Who mixed things up in the biotech world this past week? Pfizer announces its leadership team, Rheos gets a new COO, and board of directors updates from multiple biopharma companies.
New Data from Phase 2 Flu Challenge Study Demonstrates Vaxart’s Oral H1 Flu Vaccine Generated Protective Mucosal Immunity
Vaxart oral tablet vaccine provided 39% reduction in flu illness compared to 27% for Fluzone®
Vaxart ended the quarter with cash and cash equivalents of $23.9 million compared to $17.5 million at March 31, 2018.
Vaxart Announces Publication of the Phase 1 Results of its Oral Norovirus Tablet Vaccine in Journal of Clinical Investigation Insight
Vaxart, Inc. today announced publication of the comprehensive results of the previously disclosed Phase 1 clinical trial with its norovirus oral tablet vaccine in the Journal of Clinical Investigation Insight.
Vaxart, Inc. reported the topline results from a Phase 2 clinical trial evaluating the safety and efficacy of an antiviral teslexivir 5% gel.
Vaxart, Inc. announced that Wouter Latour, M.D., president and chief executive officer of Vaxart, will present a company overview at the Jefferies 2018 Global Healthcare Conference.
Vaxart, Inc. announced that Roberto Mateo, Ph.D., lead scientist of Vaxart, will present data on the Phase 1 norovirus vaccine trial in a poster presentation at the American Society of Microbiology 2018.
Vaxart, is a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection